F Dondorf1, A Ali Deeb2, A Bauschke2, P Felgendreff2,3, H M Tautenhahn2,3, M Ardelt2, U Settmacher2, F Rauchfuss2. 1. Department of General, Visceral and Vascular Surgery, Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany. Felix.Dondorf@med.uni-jena.de. 2. Department of General, Visceral and Vascular Surgery, Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany. 3. Research Program "Else Kröner-Forschungskolleg AntiAge", Jena University Hospital, Jena, Germany.
Abstract
PURPOSE: Here, we analyse the technical modification of the ALPPS procedure, ligating the middle hepatic vein during the first step of the operation to enhance remnant liver hypertrophy. METHODS: In 20 of 37 ALPPS procedures, the middle hepatic vein was ligated during the first step. Hypertrophy of the functional remnant liver volume was assessed in addition to postoperative courses. RESULTS: Volumetric analysis showed a significant volume increase, especially for patients with colorectal metastases. Pre-existing liver parenchyma damage (odds ratio = 0.717, p = 0.017) and preoperative chemotherapy were found to be significant predictors (odds ratio = 0.803, p = 0.045) of higher morbidity and mortality. In addition, a survival benefit for maintenance of middle hepatic vein was shown. CONCLUSION: This technical modification of the ALPPS procedure can accentuate future liver remnant volume hypertrophy. The higher morbidity and mortality observed are most likely associated with pre-existing parenchymal damage within this group.
PURPOSE: Here, we analyse the technical modification of the ALPPS procedure, ligating the middle hepatic vein during the first step of the operation to enhance remnant liver hypertrophy. METHODS: In 20 of 37 ALPPS procedures, the middle hepatic vein was ligated during the first step. Hypertrophy of the functional remnant liver volume was assessed in addition to postoperative courses. RESULTS: Volumetric analysis showed a significant volume increase, especially for patients with colorectal metastases. Pre-existing liver parenchyma damage (odds ratio = 0.717, p = 0.017) and preoperative chemotherapy were found to be significant predictors (odds ratio = 0.803, p = 0.045) of higher morbidity and mortality. In addition, a survival benefit for maintenance of middle hepatic vein was shown. CONCLUSION: This technical modification of the ALPPS procedure can accentuate future liver remnant volume hypertrophy. The higher morbidity and mortality observed are most likely associated with pre-existing parenchymal damage within this group.
Authors: Matthew J Edmondson; Mikael H Sodergren; Philip H Pucher; Ara Darzi; Jun Li; Henrik Petrowsky; Ricardo Robles Campos; Alejandro Serrablo; Long R Jiao Journal: Surgery Date: 2015-12-31 Impact factor: 3.982
Authors: Erik Schadde; Victoria Ardiles; Ricardo Robles-Campos; Massimo Malago; Marcel Machado; Roberto Hernandez-Alejandro; Olivier Soubrane; Andreas A Schnitzbauer; Dimitri Raptis; Christoph Tschuor; Henrik Petrowsky; Eduardo De Santibanes; Pierre-Alain Clavien Journal: Ann Surg Date: 2014-11 Impact factor: 12.969
Authors: Andreas A Schnitzbauer; Sven A Lang; Holger Goessmann; Silvio Nadalin; Janine Baumgart; Stefan A Farkas; Stefan Fichtner-Feigl; Thomas Lorf; Armin Goralcyk; Rüdiger Hörbelt; Alexander Kroemer; Martin Loss; Petra Rümmele; Marcus N Scherer; Winfried Padberg; Alfred Königsrainer; Hauke Lang; Aiman Obed; Hans J Schlitt Journal: Ann Surg Date: 2012-03 Impact factor: 12.969
Authors: Maartje A J van den Broek; Steven W M Olde Damink; Cornelis H C Dejong; Hauke Lang; Massimo Malagó; Rajiv Jalan; Fuat H Saner Journal: Liver Int Date: 2008-07 Impact factor: 5.828